Responsible patient advocacy: Perspectives from the alpha-1 foundation

American Journal of Medical Genetics, Part A

Volumn 146, Issue 22, 2008, Pages 2845-2850

  Sharp, Richard R ^a   Yarborough, Mark ^b,d   Walsh, John W ^c   Coors, Marilyn ^d   Dennis, Shirley ^d   Juengst, Eric ^d   Longstaff, Jennifer ^d   Merz, Jon ^d   Moseley, Ray ^d   Stockham, Connie ^d   Sharp, Richard ^d   Waldrop, Debbie ^d   Wanner, Adam ^d   Williams, Rob ^d  

^a LERNER RESEARCH INSTITUTE   (United States)

^b UNIVERSITY OF COLORADO   (United States)

^c Alpha 1 Foundation   (United States)

^d JJ 60 ^*

Author keywords

Alpha 1 antitrypsin; Ethics advisory board; Health policy; Patient advocacy

Indexed keywords

ADVISORY COMMITTEE; ALPHA 1 ANTITRYPSIN DEFICIENCY; CLINICAL RESEARCH; DECISION MAKING; GENETIC DISORDER; HUMAN; MEDICAL ETHICS; PATIENT ADVOCACY; PATIENT CARE; PRIORITY JOURNAL; REVIEW;

ADVISORY COMMITTEES; ALPHA 1-ANTITRYPSIN DEFICIENCY; FOUNDATIONS; HUMANS; PATIENT ADVOCACY; UNITED STATES;

EID: 56049118019     PISSN: 15524825     EISSN: 15524833     Source Type: Journal    
DOI: 10.1002/ajmg.a.32558     Document Type: Review

References (34)

1. American Thoracic Society and European Respiratory Society. 2003. American Thoracic Society/European Respiratory Society statement: Standards for the diagnosis and management of individuals with alpha-1 antitrypsin deficiency. Am J Respir Crit Care Med 168:818-900.
2. Angell M. 2004. The truth about the drug companies. New York: Random House.
3. Brantly ML, Paul LD, Miller BH, Falk RT, Wu M, Crystal RG. 1988. Clinical features and history of the destructive lung disease associated with alpha-1-antitrypsin deficiency of adults with pulmonary symptoms. Am Rev Respir Dis 138:327-336.
4. Couzin J. 2005. Advocating, the clinical way. Science 308:940-942.
5. de Serres FJ. 2002. Worldwide racial and ethnic distribution of alpha-1-antitrypsin deficiency: Summary of an analysis of published genetic epidemiologic surveys. Chest 122:1818-1829.
6. Dresser R. 2001. When science offers salvation: Patient advocacy & research ethics. New York: Oxford University Press.
7. Gildea TR, Shermock KM, Singer ME, Stoller JK. 2003. Cost-effectiveness analysis of augmentation therapy for severe alpha-1 antitrypsin deficiency. Am J Respir Crit Care Med 167:1387-1392.
8. Hay JW, Robin ED. 1991. Cost-effectiveness of alpha-1 antitrypsin replacement therapy in treatment of congenital chronic obstructive pulmonary disease. Am J Public Health 81:427-433.
9. Horng S, Grady C. 2003. Misunderstanding in clinical research: Distinguishing therapeutic misconception, therapeutic misestimation, and therapeutic optimism. IRB 25:11-16.
10. Hussain M, Mieli-Vergani G, Mowat AP. 1991. Alpha 1-antitrypsin deficiency and liver disease: Clinical presentation, diagnosis and treatment. J Inherit Metab Dis 14:497-511.
11. Laurell C-B, Eriksson A. 1963. The electrophoretic alpha 1-globulin pattern of serum in alpha 1-antitrypsin deficiency. Scand J Clin Lab Invest 15:132-140.
12. Lin AE, Terry SF, Lerner B, Anderson R, Irons M. 2003. Participation by clinical geneticists in genetic advocacy groups. Am J Med Genet Part A 119A:89-92.
13. Mullins CD, Wang J, Stoller JK. 2003. Major components of the direct medical costs of alpha-1-antitrypsin deficiency. Chest 124:826-831.
14. O'Brien ML, Buist NR, Murphey WH. 1978. Neonatal screening for alpha 1-antitrypsin deficiency. J Pediatr 92:1006-1010.
15. Perlmutter DH, Brodsky JL, Balistreri WF, Trapnell BG. 2007. Molecular pathogenesis of alpha-1-antitrypsin-deficiency-associated liver disease: A meeting report. Hepatology 45:1313-1323.
16. Sharp RR, de Serres F, Newman L, Sandhaus RA, Walsh JW, Hood E, Harry GJ. 2003. Environmental, occupational, and genetic risk factors for alpha-1 antitrypsin deficiency. Environ Health Perspect 111:1749-1752.
17. Stoller JK, Aboussouan LS. 2005. Alpha-1 antitrypsin deficiency. Lancet 365:2225-2236.
18. Stoller JK, Smith P, Yang P, Spray J. 1994. Physical and social impact of alpha 1-antitrypsin deficiency: Results of a survey. Cleve Clin J Med 61:461-467.
19. Stoller JK, Brantly M, Fleming LE, Bean J, Walsh J. 2000. Formation and current results of a patient-organized registry for alpha-1 antitrypsin deficiency. Chest 118:843-848.
20. Stoller JK, Sandhaus RA, Turino G, Dickson R, Rodgers K, Strange C. 2005. Delay in diagnosis of alpha-1-antitrypsin deficiency: A continuing problem. Chest 128:1989-1994.
21. Strange C, Dickson R, Carter C, Carpenter MJ, Holladay B, Lundquist R, Brantly ML. 2004. Genetic testing for alpha-1-antitrypsin deficiency. Genet Med 6:204-210.
22. Strange C, Stoller JK, Sandhaus RA, Dickson R, Turino G. 2006. Results of a survey of patients with alpha-1 antitrypsin deficiency. Respiration 73:185-190.
23. Teckman JH, Lindblad D. 2006. Alpha-1-antitrypsin deficiency: Diagnosis, pathophysiology, and management. Curr Gastroenterol Rep 8:14-20.
24. Terry PF. 2003. PXE International: Harnessing intellectual property law for benefit-sharing. In: Knoppers BM, editor. Populations and genetics: Legal and socio-ethical perspectives. Leiden: Martinus Nijhoff Publishers. p 377-393.
25. Terry SF, Boyd CD. 2001. Researching the biology of PXE: Partnering in the process. Am J Med Genet 106:177-184.
26. Terry SF, Davidson ME. 2000. Empowering the public to be informed consumers of genetic technologies and services. Community Genet 3:148-150.
27. Terry SF, Terry PF, Rauen KA, Uitto J, Bercovitch LG. 2007. Advocacy groups as research organizations: The PXE International example. Nat Rev Genet 8:157-164.
28. Tomashefski JF Jr, Crystal RG, Wiedemann HP, Mascha E, Stoller JK. 2004. The bronchopulmonary pathology of alpha-1 antitrypsin (AAT) deficiency: Findings of the death review committee of the national registry for individuals with severe deficiency of alpha-1 antitrypsin. Hum Pathol 35:1452-1461.
29. Turino GM, Barker AF, Brantly ML, Cohen AB, Connelly RP, Crystal RG, Eden E, Schluchter MD, Stoller JK. 1996. Clinical features of individuals with PI*SZ phenotype of alpha 1-antitrypsin deficiency. Am J Respir Crit Care Med 154:1718-1725.
30. Walsh JW, Snider GL, Stoller JK. 2006. A review of the Alpha-1 Foundation: Its formation, impact, and critical success factors. Respir Care 51:526-531.
31. Wästfelt M, Fadeel B, Henter JI. 2006. A journey of hope: Lessons learned from studies on rare diseases and orphan drugs. J Intern Med 260:1-10.
32. Weiss JO, Mackta JS. 1996. Starting and sustaining genetic support groups. Baltimore: Johns Hopkins University Press.
33. World Health Organisation. 1997. Alpha-1-antitrypsin deficiency: Memorandum from a WHO meeting. Bull World Health Organ 75:397-415.
34. Yarborough M, Sharp RR. 2006. Bioethics consultation and patient advocacy organizations: Expanding the dialogue about professional conflicts of interest. Camb Q Healthc Ethics 16:74-81.